Raskob, GE; van Es, N; Verhamme, P; Carrier, M; Di Nisio, M; Garcia, D; Grosso, MA; ... Hokusai VTE Cancer Investigators, .; + view all Raskob, GE; van Es, N; Verhamme, P; Carrier, M; Di Nisio, M; Garcia, D; Grosso, MA; Kakkar, AK; Kovacs, MJ; Mercuri, MF; Meyer, G; Segers, A; Shi, M; Wang, T-F; Yeo, E; Zhang, G; Zwicker, JI; Weitz, JI; Buller, HR; Hokusai VTE Cancer Investigators, .; - view fewer (2018) Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. New England Journal of Medicine , 378 (7) pp. 615-624. 10.1056/NEJMoa1711948.

Preview	Text (Published article) nejmoa1711948.pdf - Published Version Download (408kB) | Preview
Preview	Text (Supplementary Appendix) nejmoa1711948_appendix.pdf Download (1MB) | Preview
Preview	Text (Protocol) nejmoa1711948_protocol.pdf Download (2MB) | Preview
Preview	Text (Disclosure Forms) nejmoa1711948_disclosures.pdf Download (330kB) | Preview

Abstract

BACKGROUND: Low-molecular-weight heparin is the standard treatment for cancer-associated venous thromboembolism. The role of treatment with direct oral anticoagulant agents is unclear. METHODS: In this open-label, noninferiority trial, we randomly assigned patients with cancer who had acute symptomatic or incidental venous thromboembolism to receive either low-molecular-weight heparin for at least 5 days followed by oral edoxaban at a dose of 60 mg once daily (edoxaban group) or subcutaneous dalteparin at a dose of 200 IU per kilogram of body weight once daily for 1 month followed by dalteparin at a dose of 150 IU per kilogram once daily (dalteparin group). Treatment was given for at least 6 months and up to 12 months. The primary outcome was a composite of recurrent venous thromboembolism or major bleeding during the 12 months after randomization, regardless of treatment duration. RESULTS: Of the 1050 patients who underwent randomization, 1046 were included in the modified intention-to-treat analysis. A primary-outcome event occurred in 67 of the 522 patients (12.8%) in the edoxaban group as compared with 71 of the 524 patients (13.5%) in the dalteparin group (hazard ratio, 0.97; 95% confidence interval [CI], 0.70 to 1.36; P=0.006 for noninferiority; P=0.87 for superiority). Recurrent venous thromboembolism occurred in 41 patients (7.9%) in the edoxaban group and in 59 patients (11.3%) in the dalteparin group (difference in risk, −3.4 percentage points; 95% CI, −7.0 to 0.2). Major bleeding occurred in 36 patients (6.9%) in the edoxaban group and in 21 patients (4.0%) in the dalteparin group (difference in risk, 2.9 percentage points; 95% CI, 0.1 to 5.6). CONCLUSIONS: Oral edoxaban was noninferior to subcutaneous dalteparin with respect to the composite outcome of recurrent venous thromboembolism or major bleeding. The rate of recurrent venous thromboembolism was lower but the rate of major bleeding was higher with edoxaban than with dalteparin. (Funded by Daiichi Sankyo; Hokusai VTE Cancer ClinicalTrials.gov number, NCT02073682.)

Download activity - last month

Export as JSONCSVXML

Download activity - last 12 months

Export as JSONCSVXML

Downloads by country - last 12 months

Export as CSVJSONXML

Archive Staff Only

View Item